Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
14 studies found for:    "Enteropathy-associated T-cell lymphoma"
Show Display Options
Rank Status Study
1 Not yet recruiting Combination Chemotherapy and Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma
Conditions: Anaplastic Large Cell Lymphoma, ALK-Negative;   Anaplastic Large Cell Lymphoma, ALK-Positive;   Hepatosplenic T-Cell Lymphoma;   Peripheral T-Cell Lymphoma, Not Otherwise Specified;   Stage II Angioimmunoblastic T-cell Lymphoma;   Stage II Enteropathy-Associated T-Cell Lymphoma;   Stage III Angioimmunoblastic T-cell Lymphoma;   Stage III Enteropathy-Associated T-Cell Lymphoma;   Stage IV Angioimmunoblastic T-cell Lymphoma;   Stage IV Enteropathy-Associated T-Cell Lymphoma
Interventions: Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Vincristine Sulfate;   Drug: Etoposide;   Drug: Prednisone;   Drug: Lenalidomide;   Procedure: Peripheral Blood Stem Cell Transplantation;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Other: Laboratory Biomarker Analysis
2 Recruiting Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma
Conditions: Adult Nasal Type Extranodal NK/T-Cell Lymphoma;   Adult T-Cell Leukemia/Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-Cell Lymphoma;   B Lymphoblastic Leukemia/Lymphoma;   Blastic Plasmacytoid Dendritic Cell Neoplasm;   Burkitt Leukemia;   Central Nervous System Lymphoma;   Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma;   Diffuse Large B-Cell Lymphoma;   Enteropathy-Associated T-Cell Lymphoma;   Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue;   Grade 1 Follicular Lymphoma;   Grade 2 Follicular Lymphoma;   Grade 3 Follicular Lymphoma;   Hepatosplenic T-Cell Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle Cell Lymphoma;   Mediastinal (Thymic) Large B-Cell Lymphoma;   Mycosis Fungoides;   Nasal Type Extranodal NK/T-Cell Lymphoma;   Nodal Marginal Zone Lymphoma;   Peripheral T-Cell Lymphoma, Not Otherwise Specified;   Post-Transplant Lymphoproliferative Disorder;   Primary Cutaneous Anaplastic Large Cell Lymphoma;   Primary Effusion Lymphoma;   Sezary Syndrome;   Splenic Marginal Zone Lymphoma;   Subcutaneous Panniculitis-Like T-Cell Lymphoma;   Systemic Anaplastic Large Cell Lymphoma;   T Lymphoblastic Leukemia/Lymphoma;   Transformed Recurrent Non-Hodgkin Lymphoma
Interventions: Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Dietary Supplement: Salvia hispanica Seed
3 Recruiting A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)
Conditions: T-cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Hepato-splenic T-cell Lymphoma;   Adult T-cell Leukemia/Lymphoma;   Enteropathy Associated T-cell Lymphoma;   NK T-cell Lymphoma;   Transformed Mycosis Fungoides
Intervention: Drug: Brentuximab vedotin
4 Recruiting CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL
Conditions: Peripheral T-Cell Lymphoma;   Angioimmunoblastic T Cell Lymphoma;   ALK-negative Anaplastic Large Cell Lymphoma;   Enteropathy Associated T Cell Lymphoma;   Subcutaneous Panniculitis Like T Cell Lymphoma;   Acute Adult T-Cell Leukemia/Lymphoma
Interventions: Drug: CEOP/IVE/GDP chemotherapy regimen;   Drug: CEOP chemotherapy regimen for 6 cycles
5 Recruiting Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency
Conditions: Aggressive Non-Hodgkin Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-Cell Lymphoma;   Chronic Lymphocytic Leukemia;   Diffuse Large B-Cell Lymphoma;   Enteropathy-Associated T-Cell Lymphoma;   Hepatosplenic T-Cell Lymphoma;   Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Mediastinal (Thymic) Large B-Cell Lymphoma;   Nasal Type Extranodal NK/T-Cell Lymphoma;   Peripheral T-Cell Lymphoma, Not Otherwise Specified;   Primary Cutaneous Anaplastic Large Cell Lymphoma;   Refractory Anaplastic Large Cell Lymphoma;   Small Lymphocytic Lymphoma;   Subcutaneous Panniculitis-Like T-Cell Lymphoma
Interventions: Dietary Supplement: Cholecalciferol;   Other: Laboratory Biomarker Analysis
6 Recruiting CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma
Conditions: ALK-negative Anaplastic Large Cell Lymphoma;   Peripherial T Cell Lymphoma,Not Otherwise Specified;   Angioimmunoblastic T Cell Lymphoma;   Enteropathy Associated T Cell Lymphoma;   Hepatosplenic T Cell Lymphoma;   Subcutaneous Panniculitis Like T Cell Lymphoma
Interventions: Drug: Cyclophosphamide 750mg/m2;   Drug: Vincristine 1.4mg/m2;   Drug: Doxorubicin 50mg/m2;   Drug: prednisone 60mg/m2;   Drug: ifosfamide 2000mg/m2;   Drug: pirarubicin 50mg/m2;   Drug: pirarubicin 25mg/m2;   Drug: Etoposide phosphate 100mg/m2;   Drug: methotrexate 1500mg/m2
7 Active, not recruiting Study of MLN8237 in Patients With Advanced Hematological Malignancies
Conditions: B-cell Follicular Lymphoma;   B-cell Marginal Zone Lymphoma;   Diffuse Large B-cell Lymphoma;   B-cell Mantle Cell Lymphoma;   B-cell Small Lymphocytic Lymphoma (SLL);   B-Cell Chronic Lymphocytic Leukemia (B-CLL);   Multiple Myeloma;   Waldenstrom's Macroglobulinemia;   Noncutaneous Peripheral T-cell Lymphoma Not Otherwise Specified (PTCL-NOS);   Angioimmunoblastic T-cell Lymphoma (AITL);   Anaplastic Large Cell Lymphoma;   Enteropathy Associated T-cell Lymphoma (EATCL);   NK Lymphoma (NKL)
Intervention: Drug: MLN8237
8 Completed Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma
Conditions: Peripheral T-cell Lymphoma (Not Otherwise Specified);   Angioimmunoblastic T-cell Lymphoma;   Extranodal NK/T-cell Lymphoma Nasal Type;   Enteropathy- Type T-cell Lymphoma;   Hepatosplenic T-cell Lymphoma;   Anaplastic Large Cell Lymphoma (ALCL) (ALK-1 Negative);   Relapsed ALCL (ALK-1 Positive) Post Autologous Transplant
Intervention: Drug: panobinostat and bortezomib
9 Recruiting CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma
Conditions: Acute Myeloid Leukemia;   Precursor T-Cell Lymphoblastic Leukemia-Lymphoma;   T-cell Prolymphocytic Leukemia;   T-cell Large Granular Lymphocytic Leukemia;   Peripheral T-cell Lymphoma, NOS;   Angioimmunoblastic T-cell Lymphoma;   Extranodal NK/T-cell Lymphoma, Nasal Type;   Enteropathy-type Intestinal T-cell Lymphoma;   Hepatosplenic T-cell Lymphoma
Intervention: Biological: anti-CD7 CAR-pNK cells
10 Unknown  High-Dose Chemotherapy Given Together With Peripheral Blood Stem Cell Transplant in Treating Patients With Intestinal T-Cell Lymphoma
Conditions: Lymphoma;   Small Intestine Cancer
Interventions: Drug: carmustine;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: doxorubicin hydrochloride;   Drug: epirubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: melphalan;   Drug: methotrexate;   Drug: prednisolone;   Drug: vincristine sulfate;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: biopsy;   Procedure: peripheral blood stem cell transplantation
11 Recruiting MAgnetic Resonance Imaging in COeliac Disease
Conditions: Celiac Disease;   Coeliac Disease;   Celiac Sprue;   Gluten Enteropathy
Intervention: Other: Gluten free diet
12 Terminated Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma
Conditions: 714leukemia;   Lymphoma
Interventions: Drug: Bortezomib;   Drug: Everolimus
13 Terminated
Has Results
Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma
Condition: Lymphoma
Interventions: Drug: Vorinostat;   Drug: Bortezomib
14 Completed
Has Results
SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma
Condition: Lymphoma
Interventions: Drug: Zolinza (vorinostat);   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisone

Indicates status has not been verified in more than two years